BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chappuis F, Farinelli T, Deckx H, Sarnecki M, Go O, Salzgeber Y, Stals C. Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study. Vaccine 2017;35:1448-54. [PMID: 28190741 DOI: 10.1016/j.vaccine.2017.01.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Shouval D. Immunization against Hepatitis A. Cold Spring Harb Perspect Med 2019;9:a031682. [PMID: 29661808 DOI: 10.1101/cshperspect.a031682] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Kozlowski PA, Aldovini A. Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission. Curr Immunol Rev 2019;15:102-22. [PMID: 31452652 DOI: 10.2174/1573395514666180605092054] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
3 Minakshi P, Ghosh M, Kumar R, Brar B, Lambe UP, Banerjee S, Ranjan K, Kumar B, Goel P, Malik YS, Prasad G. An Insight into Nanomedicinal Approaches to Combat Viral Zoonoses. Curr Top Med Chem 2020;20:915-62. [PMID: 32209041 DOI: 10.2174/1568026620666200325114400] [Reference Citation Analysis]
4 Li Y, Xiao Y, Chen Y, Huang K. Nano-based approaches in the development of antiviral agents and vaccines. Life Sci 2021;265:118761. [PMID: 33189824 DOI: 10.1016/j.lfs.2020.118761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Cimica V, Galarza JM. Adjuvant formulations for virus-like particle (VLP) based vaccines. Clin Immunol. 2017;183:99-108. [PMID: 28780375 DOI: 10.1016/j.clim.2017.08.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
6 Hobernik D, Bros M. DNA Vaccines-How Far From Clinical Use? Int J Mol Sci 2018;19:E3605. [PMID: 30445702 DOI: 10.3390/ijms19113605] [Cited by in Crossref: 144] [Cited by in F6Publishing: 132] [Article Influence: 36.0] [Reference Citation Analysis]
7 Nardo D, Henson D, Springer JE, Venditto VJ. Modulating the immune response with liposomal delivery. Nanomaterials for Clinical Applications. Elsevier; 2020. pp. 159-211. [DOI: 10.1016/b978-0-12-816705-2.00006-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Lemon SM, Ott JJ, Van Damme P, Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol 2017:S0168-8278(17)32278-X. [PMID: 28887164 DOI: 10.1016/j.jhep.2017.08.034] [Cited by in Crossref: 103] [Cited by in F6Publishing: 80] [Article Influence: 20.6] [Reference Citation Analysis]
9 Samara KA, Barqawi HJ, Aboelsoud BH, AlZaabi MA, Alraddawi FT, Mannaa AA. Hepatitis A virus knowledge and immunization attitudes and practices in the United Arab Emirates community. Sci Rep 2021;11:2651. [PMID: 33514776 DOI: 10.1038/s41598-020-80089-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence. Hum Vaccin Immunother 2021;17:1496-519. [PMID: 33325760 DOI: 10.1080/21645515.2020.1819742] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang L. Hepatitis A vaccination. Hum Vaccin Immunother 2020;16:1565-73. [PMID: 32649265 DOI: 10.1080/21645515.2020.1769389] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sulczewski FB, Liszbinski RB, Romão PRT, Rodrigues Junior LC. Nanoparticle vaccines against viral infections. Arch Virol 2018;163:2313-25. [PMID: 29728911 DOI: 10.1007/s00705-018-3856-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]